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ABSTRACT
This review describes several aspects of the management of precocious puberty (PP) and
variants in girls and boys.
PP is characterized by early pubertal changes, acceleration of growth velocity and rapid
bone maturation that often result in reduced adult height. Onset of pubertal signs before the
age of 8 years in girls and 9 years in boys should always be evaluated carefully. The main prin-
ciples of therapy are to stop the progression of secondary sex characteristics and menses (in
girls), to increase final adult height, to promote psychosocial well-being, and to treat the
underlying cause if known.
Conflict of interest: None declared
Precocious puberty (PP) is defined as the
development of pubertal changes, at an
age younger than the accepted lower limits
for age of onset of puberty, namely, before
age 8 years in girls and 9 years in boys. PP
is responsible for early progression of sec-
ondary sexual characteristics, rapid bone
maturation, reduced final height, inappro-
priate body appearance and psychological
behavioral abnormalities. Indications for
treatment are based on the progression rate
of puberty, advancement of bone age, pre-
dicted adult height and psychological eval-
uation. This paper will focus on central
precocious puberty (CPP), normal variant
puberty, and current management princi-
ples for these conditions.
According to the classical definition,
onset of secondary sexual characteristics as
Tanner Stage 2 in a girl before age 8 years,
or in a boy before age 9 years is defined as
PP. However, according to two studies
from USA, the onset of puberty may be as
early as 7.7 years in girls and as early as
7.6 years in boys.
1 Although there is no
consensus, breast development in girls
aged between 7-8 years is defined as the
“gray zone” and this clinical phenomenon
has been referred to as “accelerated puber-
ty, early normal puberty, or rapid progres-
sive thelarche variant”. Majority of these
girls do not require treatment and reach a
final height which is appropriate for their
target height. 
It may be hard to diagnose PP in a
child with minimal symptoms. Especially
in girls, PP diagnosis should be confirmed
by showing increase in gonadotropin
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and/or sex steroids levels, accelerated
somatic development and bone age
advancement. Follow-up of the early signs
of sexual development is also important. If
these signs do not progress at follow-up,
early breast development can be accepted as
a normal variant. 
PP may be classified as gonadotropin
dependent, progressive (central/true PP) or
gonadotropin independent (peripheral/pseu-
do PP). The hypothalamus, pituitary and
gonad (HPG) axis is active in both physio-
logical puberty and central true PP.
However, pseudo- or peripheral PP is inde-
pendent of gonadotropin secretion and there
is no activation of the HPG axis. The source
of sex steroids is exogenous and/or endoge-
neous in this subgroup. The etiological clas-
sification of PP is seen in Table 1. 
CENTRAL PRECOCIOUS PUBERTY (CPP)
CPP is due to early maturation of the HPG
axis. The frequency of CPP ranges between
1/5000-1/10,000.
2,3 It is more common in girls.
Female/male ratio changes between 3/1 and
23/1.
4 It is reported to be more frequent in
adopted children in developed countries.
5
Although the large majority of CPP is
idiopathic, organic lesions as well as envi-
ronmental factors and substrates that mimick
hormones (endocrine disrupting chemicals)
may have estrogen activity or may cause an
increase of endogenous estrogen secretion.
Cosmetic products, foods and some pharma-
cological insecticides can disturb the HPG
axis and result in PP.
6,7
Many researchers have shown that child-
hood obesity may be associated with early
menarche in girls. Increased caloric intake
and consumption of fast foods, decreased
physical activity and prolonged television
watching duration are the factors that may
cause obesity.
6,8
The relationship between intrauterine
growth retardation, premature adrenarche
and early menarche has also been brought
to attention in recent years.
9
Although the frequency of central true
PP is rare, the progressive decrease in age
of breast development noted particularly in
the second half of the 20th century, drew
attention to a need for reconsideration of
the age of normal puberty. Endocrine dis-
turbances, obesity and low birth weight, are
among factors which have been held
responsible for increased frequency of the-
larche variants in PP distribution, so that
there seems to be a need for new defini-
tions in the 21st century. 
The etiology of CPP cannot be estab-
lished in many cases in girls and the con-
dition is accepted as idiopathic. Cerebral
Table 1: Etiological classification of precocious puberty
1- Central True Precocious Puberty
(Gonadotropin dependent)
a) Idiopathic (familial/nonfamilial)
b) CNS Tumors
- Astrocytoma, optic glioma
- Hypothalamic hamartoma
- Craniopharyngioma, ependynoma
c) Other CNS Lesions
- Abscess, encephalitis, trauma
- Hydrocephally
- Arachnoid cyst
- Cranial radiation
- Chemotherapy
d) Combined (secondary) precocious puberty
- McCune-Albright Syndrome, Congenital Adrenal Hyperplasia
2- Pseudo or Peripheral Precocious Puberty
(Gonadotropin independent)
a) Gonadal
- McCune Albright Syndrome
- Familial Testotoxicosis (activating mutation of LH receptor)
- Ovarian tumors
- Leydig cell tumor 
b) Adrenal
- Congenital virilizing adrenal hyperplasia
- Adrenal functional adenoma/carcinoma
c) Human chorionic gonadotropin producing tumors
- CNS: chorioepitelioma, dysgerminoma, teratoma
- Choriocarcinoma, hepatoma, teratoma
d) Others
- Primary hypothyroidism
- Iatrogenic
3- Normal variant puberty
a) Premature thelarche
b) Premature adrenarche
CNS: central nervous system
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lesions are found in a small minority of the
cases. It is known that the risk for CPP is
increased in patients with neurofibromato-
sis type 1, hydrocephaly, meningomyelo-
cele, neonatal encephalopathy and in
those exposed to low-dose cranial radia-
tion. 
While girls are prone to PP, delayed
puberty is more frequent in boys. However,
the risk of CPP due to organic causes is
higher in boys. One of the most common
observed pathologies is hypothalamic
hamartoma. However, central nervous sys-
tem abnormalities, especially lesions in the
hypothalamic region may not be easily
shown by imaging methods.
Hypothalamic hamartomas are congeni-
tal, non-neoplastic, and tumor-like lesions.
Some hamartomas present with gelastic
seizures and are resistant to anticonvulsant
treatment.
10 The suspicious symptoms for
hypothalamic hamartoma can be listed as:
5
1. Occurrence of PP before 2 years (gener-
ally 4 years) of age
2. PP being gonadotropin dependent
3. Presence of isointense tumor on magnet-
ic resonance imaging with gadolinium
4. Negative tumor markers for pseudo PP.
Hamartomas are more frequent in males.
CPP caused by hamartoma occurs earlier,
even before 4 years, when compared to
idiopathic and other organic etiologies in
both sexes.
The tissue in hypothalamic hamartomas
includes GnRH neurons. These ectopic neu-
rons are functional and secrete GnRH
episodically. Transforming growth factor-
alpha receptors that express astrogial cell are
also found in hamartomas. The frequency of
clinical CPP with hypothalamic hamartomas
before 4 years of age is 10%.
2
The risk of CPP is higher in cases diag-
nosed as malignancy and who have received
radiotherapy and chemotherapy. However,
if growth hormone deficiency is associated,
the acceleration in growth may not be evi-
dent. A similar condition is present in neu-
rofibromatosis type 1. The first clinical
symptom in children with optic glioma
would be CPP. If it is not diagnosed, it may
progress to complete blindness. 
Other causes that should be considered
are the gene mutations that cause PP. The
family investigations especially on recently
defined GRP54 receptor gene in idiopathic
cases and its ligand kisspeptin, and GnRH
receptor gene will increase the information
in this field.
11
COMBINED SECONDARY CENTRAL
PRECOCIOUS PUBERTY
Acceleration in somatic development
and advancement in bone age are
inevitable findings when the patient is
exposed to high level of sex steroids in a
long period. This results in an earlier
puberty and HHG axis matures depending
on the somatic development, rather than
chronological age. The most common eti-
ology for this situation is the congenital
adrenal hyperplasia. Testotoxicosis and
McCune-Albright syndromes were also
defined as rare causes.
5 All peripheral
pseudo PP cases without management
would become complicated when CPP is
superimposed. The onset of CCP is related
to the degree of somatic development.
Generally it starts when bone age reaches
10-13 years. However, in some patients it
starts just 1 month after the onset of the
treatment for pseudo PP.
12 Secondary CPP
is permanent and requires treatment.
PSEUDO- OR PERIPHERAL PRECOCIOUS
PUBERTY (PPP)
In girls one of the most common etiolo-
gies of PPP is ovarian follicular cysts.
These cysts may cause vaginal bleeding in
younger girls. Pelvic ultrasonographic
evaluation is very useful in such occa-
sions. In some cases, especially with small
cysts, there may be regression by time,
and estrogen level decreases. These cases
are generally the ones who were followedas premature menarche in the past.
Although it is not justified, premature
menarche cases are not accepted as nor-
mal variant and their follow-up for PPP is
recommended.
Granulosa- theca cell cysts or tumors are
generally bigger than follicular cysts.
The classical triad of McCune-Albright
Syndrome includes café-au-lait spots, polio-
static fibrous dysplasia and PPP. It occurs
due to the mutation that activates the gene
encoding Gs protein-alpha subunit. It should
be kept in mind in children who have recur-
rent follicular cysts and irregular vaginal
bleeding even without other signs. It may
have incomplete forms. The other endocrine
organ hyperfunctions (hyperthyroidism,
Cushing syndrome, acromegaly, and hypop-
hosphatemic rickets) should be investigated.
Bone scintigraphy is necessary in these
cases.
LH receptor activating mutations (familial
testotoxicosis) are autosomal dominant rare
diseases in male children. It is characterized
by symmetrical testicular enlargement.
McCune Albright syndrome is rare in boys.
HCG secreting tumor is another cause of
PPP in boys. It may be located in organs
other than gonads, such as liver due to
hepatoblastoma, pineal region, brain or
mediastinum. This results in testicular
enlargement and elevation in serum testos-
terone levels. Leydig cell tumors are gener-
ally benign and cause unilateral testis
enlargement.
2 PPP etiologies in both sexes
which were stated up to here are isosexual.
Virilizing diseases that arise from adrenal
gland, especially congenital adrenal hyper-
plasia, are the most common PPP etiological
factors in childhood. Although it causes iso-
sexual PPP in boys, it results in heterosexu-
al PPP in girls.
Chronic primary hypothyroidism
Significant TSH increase in some prepu-
bertal children causes an increase in FSH
level and results in occurrence of pubertal
signs. Early breast development in girls and
mild testicular enlargement in boys compose
the clinical signs. Acceleration in somatic
development is not seen. Increase in pro-
lactin level and galactorrhea may accompa-
ny the pubertal signs. The treatment of
hypothyroidism causes a recovery.
2
PREMATURE THELARCHE
Premature thelarche typically starts before
2 years of age and breast development is
isolated. It may be unilateral. Somatic devel-
opment is not accelerated. The bone age is
not advanced. Breast development may be
cyclical in relation to blood estrogen levels.
The situation regresses by time. The same
regression is not observed in cases that start
after 2 years of age and have significant
glandular structure. Primary hypothyroidism
should be ruled out in these cases.
The follow-up for PP is necessary in cases
that were defined as thelarche variant.
Premature thelarche which starts after 2 years
of age may progress to CPP.
2 Advancement in
bone age, ovarian enlargement and higher
estrogen levels may accompany premature
thelarche in borderline cases.
The physiologic baseline event in pre-
mature thelarche is the increase in FSH
level. Inhibin B secreted from granulosa
cells is thought to be responsible for this
increase.
13 FSH response is the foreground
both in night pulses and peak response to
GnRH stimulus. LH response together with
FSH may increase to higher levels in pre-
mature thelarche cases that start before 2
years of age, and it may interfere with CPP.
This phenomenon has been termed as
“mini-puberty”.
14 However, ovaries and
uterus are within prepubertal sizes, but
these measurements must be performed by
an experienced physician. The follow-up of
progression rate and growth tempo are
important in these cases. Another point
which should be kept in mind is, that some
of the premature thelarche cases are due to
exposion of estrogenic environmental pol-
lution.
6
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Premature adrenarche/pubarche
Adrenarche is the increase of pubertal
adrenal androgens. It may be seen in both
sexes in normal children between 6-8 years
of age. Generally pubarche, that is, genital
and axillary hair, does not accompany this
situation. However, adrenarche is associated
with pubarche in some children, and this is
the most innocent form of the premature
pubarche. It is important to distinguish this
situation from pathologic etiologies. 
Adrenarche occurs as a result of increa-
sed secretion of androgens from zona reticu-
laris from the adrenal cortex. It results in an
increase of serum DHEA and its metabolite
sulfate due to an increase in 17, 20 liyase
and 17 alpha hydroxylase activities. Increase
in serum level of DHEA-S over 40 μg/dl is
the biochemical indicator of the adrenarche.
This increase may be exaggerated in some
cases, and may increase up to 200 μg/dl. In
a recent study it was shown that androgen
receptor gene activity increase due to dec-
reased receptor gene methylation pattern
can be seen in some cases.
15
Congenital adrenal hyperplasia or adre-
nal tumors, in which androgen production
is increased, are the pathologies which
should be ruled out initially in premature
pubarche. Some partial enzyme deficiencies
such as 21-OH and 3β OHD deficiency may
manifest first with premature pubarche.
Both somatic growth and advancement in
bone age are accelerated in these cases; so
that DHEA-S measurement should be per-
formed in addition to testosterone and
17OHP. Although DHEA-S is increased in
isolated premature pubarche, testosterone
and 17OHP levels are in normal ranges.
Sometimes, ACTH stimulation test is neces-
sary in borderline cases for diagnosis.
Onset of puberty in cases with premature
adrenarche is generally expected in normal
time. Final heights must be compatible with
their genetics. However, prepubertal
growth tempo may slightly be increased.
This condition does not affect the onset and
progression of normal puberty. In some
conditions, gonadarche (HPG axis activa-
tion) may accompany adrenarche, so that,
the follow-up of cases at 4-6 month inter-
vals is suggested.
Recently the association of ovarian
hyperandrogenism (polycystic ovary syn-
drome), hyperinsulinism and dyslipidemia
observed in some girls with premature pub-
arche has gained importance.
16,17 Premature
pubarche may be the earlier sign of meta-
bolic syndrome in childhood. Hyperinsuli-
nism in these cases may be the result of
diminished fetal growth rate and intrauterine
growth retardation.
9,18-20
There is risk for early menarche in some
cases with onset of pubarche between 7-8
years. The predicted adult height is also
affected in some cases. It has been observed
that 45% of girls with premature pubarche
developed polycystic over syndrome in
time.
2 Although some cases have low birth
weight, some may be in normal weight
ranges.
2 Family history of girls with prema-
ture pubarche should be evaluated for meta-
bolic syndrome and these girls should be fol-
lowed for this risk independent of their birth
weight. Today the question of which patients
in gray zone carry this risk is not clarified,
and is a research subject. The audit of hyper-
insulinism and increase of insulin sensitivity
in low-birth weight patients may prevent
early menarche in some cases in the future.
21
CLINICAL SIGNS AND DIAGNOSIS
PP is associated with accelerated growth,
advanced bone age, development of second-
ary sex characteristics and early closure of
epiphysis. Defining the etiologic cause is
important for the management of the under-
lying disease. History should be sought for
information about the onset of the signs, pro-
gression rate, and growth tempo in the last 6-
12 months, presence of secondary sex char-
acteristics (acne, oily skin, erection, night
ejaculation and vaginal bleeding) in addition
to the presence of pubertal signs. History of
PP in family supports the diagnosis of famil-ial forms. Pubertal staging should be per-
formed according to Tanner-Marshall method
on physical examination, and anthropometric
evaluations should be defined by measure-
ment of weight, height and body proportions.
All old and new data should be marked on
growth chart. Growth velocity per year must
be calculated. If there is not any data for the
past, patient should be followed prospective-
ly for at least 6 months. Growth velocity is
more than 75th percentile in most patients
with CPP. Bone age should be determined by
left hand and wrist X-ray. If bone age is
advanced more than 2SD for chronological
age it is unlikely the child has a normal vari-
ant of pubertal development.
5 If it is possible,
Δ bone age/ Δ chronological age must be cal-
culated. If this ratio is greater than 1.2, it is in
favor of progressive CPP. 
If testis volume is smaller than 4 ml in
the presence of secondary sex characteristics
in a boy, this PP is probably caused by adre-
nal pathologies. Asymmetric testicular
enlargement is observed in McCune-Albright
syndrome and Leydig cell tumor cases,
whereas bilateral testicular enlargement is
common in testotoxicosis, hCG secreting
tumors and CPP cases. Testis enlargement is
in moderate degree, and never exceeds
Tanner 3 in testotoxicosis and hCG secreting
tumors. Cases with only one of the pubertal
signs, without accelerated growth and
advanced bone age can be accepted as nor-
mal variant, but should be followed-up.
The first endocrinological evaluation
includes the measurement of gonadotropins
(LH, FSH) and related sex steroids. Old
radioimmunassay kits are not definitive in
baseline gonadotropin evaluation for differ-
entiation between CPP and PPP. The patient
must be evaluated by GnRH stimulation test.
However, third generation sensitive
immunochemilumimetric (ICMA) measure-
ments are sensitive at basal evaluation, but
GnRH test is still the most important differ-
ential diagnostic test. Although FSH
response is dominant in premature the-
larche, LH is the dominant gonadotropin in
CPP patients. LH and FSH are suppressed or
at prepubertal levels in PPP cases. 0 and 30
minute samples may be sufficient on intra-
venous GnRH test.
5 There is no evidence for
a superior response in prolonged tests.
5 In
premature thelarche cases that are younger
than 2 years old; LH may increase in addi-
tion to FSH, but dominant response is still
FSH. There is a pubertal response of LH to
GnRH in CPP patients.
5 Organic/idiopathic
etiological evaluation can not be done by
only hormonal levels for CPP.
22
The diagnosis of CPP should not be
based on hormonal data and it must be com-
bined with clinical signs and follow-up.
Basal plasma testosterone level in boys
increase both in CPP and PPP, but it is much
higher in PPP patients. The importance of
oestrogen level is limited in girls with CPP,
because in many affected girls it has been
shown in low ranges.
3 The other endocrino-
logical evaluations may include thyroid tests,
17OHP level and hCG measurement
depending on the clinical signs. 
Pelvic ultrasonography is another test
that should be performed in girls. Ovarian
and uterine sizes should be compared with
reference levels. Increase in ovarian volumes
are important especially in CPP cases.
Bilateral enlarged ovaries can be determined
in CPP patients. Uterine volume is pubertal
in all CPP cases.
23 Although structure of
ovaries (microcystic/macrocystic/ follicular),
follicule diameter, fundus/ cervix ratio, uter-
ine length and endometrium thickness are
important parameters, many experts report-
ed that these were not determinant in differ-
ential diagnosis between premature the-
larche and CPP. Ovaries may be asymmetri-
cally enlarged in girls with gonadal PPP.
Ovaries show microcystic structure on ultra-
sonography in prepubertal ages. Uterine
shape is tubuler, endometrium is thin.
Ovaries are smaller than 2 ml, and uterine
length is smaller than 4 cm.
23 By contrast
ovaries are macrocystic/follicular on puber-
tal ultrasonography. Uterine is in “pear” sha-
pe and endometrium is thickened.
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Cranial and pituitary magnetic resonance
imaging (MRI) should be performed to rule
out organic CPP. Although there has been a
suggestion to perform MRI in only male CPP
cases or in girls below 6 years old, today it is
accepted that MRI should be done for all
cases because intracranial tumors may cause
CPP in all ages.
2,5,8,24 However, imaging needs
to be repeated periodically in cases who are
below 4 years and were reported to be nor-
mal. It is important that the MRI images be
evaluated by expert radiologists. Flow charts
for PP in boys and girls are shown on Figure
1 and Figure 2.
CURRENT MANAGEMENT APPROACHES
There is no consensus about the treatment
indications for CPP. Treatment options may
depend on the presence of psychological/be-
havioral disorders, anxiety about height and
probability of early menarche. Families and
physicians should discuss the risks and deci-
de on the treatment together. Although
psychological influences of PP have not been
investigated sufficiently, there are some case
reports about sexual abuse and early preg-
nancy. Psychological indication should be ba-
sed on the patient individually.
There is not a hesitance about the initiation
of treatment for cases younger than 7 years old.
However, especially for patients between 7-8
years, rapid advancement in bone age, more
than 1 SD loss in predicted adult height and
probability of menarche before 10 years old
compose the concrete criteria for treatment.
However, there is not a treatment indication for
slowly progressive CPP without loss in height
potential.
25 GnRH analogues have been used
for suppressing HPG axis since 1981. Their
effects depend on desensitization and down-
regulation of GnRH receptors. They are safe
and have minimal side effects. 
The most commonly used one, which
has also been added to indication list in our
country, is the leuprolide acetate depot
form. Recently, subcutaneous form which is
less painful and can be applied at 3 to 4
week intervals is on market. In the first
months of the treatment, there can be exac-
erbation in signs which may result in vaginal
bleeding in girls, but this effect is infrequent
than expected. Some minor menopausal
signs have been defined. The depression
that was reported in adults has not been
defined in children yet. Although there have
been studies concerning body proportions,
obesity and psychological effects, they are
not evidence-based. The suggested regimen
is 0.3 mg/kg/28 days. The experience with 3
month depot form is limited.
Effective GnRH agonist treatment can be
succeeded only by efficient Gn suppression.
Bone age, growth velocity, uterine and ovari-
an sizes and breast development should be
followed closely during the treatment. The
treatment does not affect the pubic hair. LH
suppression should be checked by iv GnRH
test at 3-6th month of the treatment. Follow-up
with oestrogen levels is not recommended.
HPG axis returns to its previous situation
after the cessation of the treatment. The
most frightening side effect, especially in
patients who received growth hormone for
suppressed growth due to GnRH agonist
treatment, is the development of polycystic
ovaries.
26 There is not any information about
the long term follow-up of those patients in
the literature. However, we have informa-
tion about the final height. Results are slight-
ly better in boys when compared to girls.
5
The use of GnRH analogues, especially after
7.5 years, does not have effect on final
height.
23 However, final height results are
better when compared to untreated PP
patients. 75% of patients reach their genetic
potential, and height is > 150 cm in 90%.
28
Agonist treatment does not cause osteopenia
or osteoporosis. Body proportions were
reported to be better when compared to
untreated patients.
5
A new treatment option, is histrelin, sub-
cutaneous implant of GnRH agonist.
30 It was
developed to decrease the monthly hospital
visits. There is a new research on using both
agonist and short acting antagonist to sup-Early breast development in girls
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Figure 1: Flow chart for breast development in girls
Berbero¤lu M.
J Clin Res Ped Endo 2009;1(4):164–174 171Precocious Puberty and Normal Variant Puberty
© 2009 Journal of Turkish Pediatric Endocrinology and Diabetes Society 172
Early genital development in boys
Accelerated growth velocity and
advanced bone age
Organic
precocious
puberty
↓, N Testosterone
LH ↑
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↓FSH and LH 
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puberty
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treatment Pseudo precocious
puberty
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↑17 OHP
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Aromatase
inhibitors for
treatment
GnRH agonist
treatment
Congenital adrenal
hyperplasia
FSH: follicle stimulating hormone, LH: luteinizing hormone, CNS: central nervous system;
GnRH: gonadotropin releasing hormone, hCG: human chorionic gonadotropin,
17OHP: 17 hydroxyprogesterone
Figure 2: Flow chart for precocious puberty in boyspress the exacerbation in the first months,
but all are experimental studies.
PPP treatment options are anti-oestrogens
like tamoxifen or aromatase inhibitors such as
anastrozole.
32 Pamidronate constitutes the
current option in the treatment of fibrous dys-
plasia in McCune Albright Syndrome.
3
CONCLUSION
There are three questions to be answered
when faced with PP.
1. Is PP a normal variant or an abnormal
sign?
2. If it is abnormal, is it central or peripher-
al, and if it is peripheral, is it adrenal or
gonadal?
3. If it is central, is it idiopathic or related to
an intracranial pathology? Is there an in-
dication for treatment?
If these questions are answered, data
about approach and management are evi-
dence-based and clear. Treatment indication
in intermediate forms depends on cost ben-
efit ratio. Close follow-up of all patients con-
stitutes the main aspects of the management.
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